Biochemical and behavioural properties of clozapine D. M. CowardA. ImperatoT. G. White OriginalPaper Pages: S6 - S12
Basic biology of clozapine: electrophysiological and neuroendocrinological studies Gary A. GudelskyJ. Frank NashHerbert Y. Meltzer OriginalPaper Pages: S13 - S17
Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia Herbert Y. Meltzer OriginalPaper Pages: S18 - S27
D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics L. FardeF. A. WieselG. Sedvall OriginalPaper Pages: S28 - S31
Clozapine — pharmacokinetic investigations and biochemical effects in man M. Ackenheil OriginalPaper Pages: S32 - S37
Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age C. HaringU. MeiseH. Hinterhuber OriginalPaper Pages: S38 - S40
Effect of neuroleptics on positive and negative symptoms and the deficit state J. AngstH. H. StassenB. Woggon OriginalPaper Pages: S41 - S46
Clozapine: neuroleptic-induced EPS and tardive dyskinesia Daniel E. Casey OriginalPaper Pages: S47 - S53
Clozapine pharmacology and tardive dyskinesia Jeffrey LiebermanCeleste JohnsJohn Kane OriginalPaper Pages: S54 - S59
Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial John M. KaneGilbert Honigfeldthe Clozaril Collaborative Study Group OriginalPaper Pages: S60 - S63
Predictors of response to clozapine therapy Gilbert HonigfeldJohn Patin OriginalPaper Pages: S64 - S67
A prospective study of clozapine in treatment-resistant schizophrenic patients H. Y. MeltzerB. BastaniJ. Sharpe OriginalPaper Pages: S68 - S72
Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients D. NaberM. LeppigH. Hippius OriginalPaper Pages: S73 - S76
Clozapine in the treatment of 121 out-patients M. LeppigB. BoschH. Hippius OriginalPaper Pages: S77 - S79
A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period Leif H. Lindström OriginalPaper Pages: S84 - S86
Clozapine in China: a review and preview of US/PRC collaboration William Z. PotterGrant N. KoWenwei Yan ReviewPaper Pages: S87 - S91
Long-term experience with clozapine in Denmark: research and clinical practice J. GerlachE. O. JørgensenI. Peacock OriginalPaper Pages: S92 - S96
Side effects of clozapine Hans Jörg GaertnerEberhard FischerJoachim Hoss OriginalPaper Pages: S97 - S100
Tolerability of long term clozapine treatment M. SchmaussR. WolffE. Rüther OriginalPaper Pages: S105 - S108
Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMÜP program R. GrohmannL. G. SchmidtE. Rüther OriginalPaper Pages: S109 - S112
Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies Frans H. J. Claas OriginalPaper Pages: S113 - S117
Leponex — associated granulocytopenia: a review of the situation P. KruppP. Barnes OriginalPaper Pages: S118 - S121
Development of the Clozaril Patient Management System Bijan BastaniLarry D. AlphsHerbert Y. Meltzer OriginalPaper Pages: S122 - S125
